Background: Coronavirus disease 2019 (COVID-19) was originated first in Wuhan, China in December 2019
and it is known to be caused by severe acute respiratory syndrome coronavirus-2 (SARS CoV-2). The management of
COVID-19 could be achieved by means of usage of the repurposed drugs inhibiting the viral entry and/or viral fusion such
as umifenovir, Baricitinib, Camostat mesylate, Nafamostat mesylate, and the drugs blocking the viral replication which
include favipiravir, remdesivir, Lopinavir/ritonavir, Ribavirin, Sofosbuvir, chloroquine and Hydroxychloroquine.
Objective: Along with the drugs that target the SARS-CoV-2 virus, adjunctive therapies are also employed. This review
focuses on the adjuvant therapies employed to manage the COVID-19-associated complications such as cytokine storm,
acute respiratory distress syndrome (ARDS), respiratory failure, cardiac injury, coagulopathy, and multi-organ failure.
Methods: The literature was searched in databases such as Medline/PubMed Central/PubMed, Google Scholar, Science
Direct, EBSCO, Scopus, EMBASE, Directory of open access journals (DOAJ), and reference lists to identify relevant
Results: Various studies have been identified for the use of corticosteroids, interferons, monoclonal antibodies, etoposide,
ruxolitinib, anticoagulants, convalescent plasma, immunoglobulins, mesenchymal stem cells, natural killer (NK) cells, and
inhaled nitric oxide (NO) as adjuvant therapy to manage the patients with COVID-19 along with the repurposed drugs
Conclusion: The safety and efficacy of adjuvant therapy are needed to be confirmed by various ongoing randomized
controlled clinical trials.